Visit Cynvenio at ASBC 2017 in Las Vegas, NV.
March 9, 2017 – Cynvenio will showcase its ClearID Total Insight Monitoring service at the 34th Annual Miami Breast Cancer Conference, the Young Survival Coalition (YSC) Summit, and the 27th Annual Interdisciplinary Breast Center Conference.
March 9, 2017 – Cynvenio Biosystems, Inc., a leader in personalized medicine technology and cancer diagnostics, today announced the availability of ClearID® Total Insight™ Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
February 23, 2017 – Cynvenio and Color announces a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Cynvenio’s ClearID® Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.
February 10, 2017 – Cynvenio Biosystems will feature its LiquidBiopsy rare cell isolation platform at Molecular Med Tri-Con 2017, February 19-24, 2017 in San Francisco.
January 26, 2017 - Cynvenio Biosystems, Inc. and Milenia Labs announced a distribution agreement for Cynvenio’s ClearID® Breast Cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.
January 9, 2017 - Cynvenio has released its updated ClearID® Breast Cancer blood test. The new ClearID test identifies circulating tumor cell burden and detects emergent genetic alterations associated with resistance to therapy, and has been optimized to monitor patients with advanced breast cancer during initiation of therapy and at regular intervals following treatment.
December 22, 2016 - An MLO special feature article written by Cynvenio Chief Medical Officer, Dr. Paul Song discussing liquid biopsy as a promising new approach to monitor TNBC patients post-treatment.
Cynvenio's LiquidBiopsy workflow will be showcased at the Thermo Fisher Scientific booth.
August 11, 2016 - Article in Clinical Lab Products (CLP) magazine by Cynvenio Chief Science Officer, Paul Dempsey, PhD, discussing improvements in liquid biopsy techniques and the analysis of rare cancer-derived events present among normal cells or DNA.
July 12, 2016 - BioTech Nation interview with Dr. Paul Dempsey about Cynvenio's technology and the ongoing clinical study of women with breast cancer.
June 20, 2016 - An Interview with Paul W. Dempsey, PhD, and Paul Y. Song, MD, of Cynvenio.
May 25, 2016 - Jim Cramer interviews Thermo Fisher Scientific CEO, Marc Casper. In this segment, Casper discusses Cynvenio and LiquidBiopsy.
May 9, 2016 - Article published by Clinical Lab Products discussing the results of Cynvenio's study.
April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.
April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.
Dr. Kristi Funk, Angelina Jolie's surgeon and co-founder of the Pink Lotus Breast Center, discusses Cynvenio's new clinical research study for women with triple negative breast cancer (TNBC).
March 3, 2016 – Cynvenio Biosystems, Inc. honors Triple Negative Breast Cancer Day by launching a clinical trial for women with triple negative breast cancer (TNBC) using the company’s non-invasive liquid biopsy technology to monitor participants and identify early signs of metastasis.
February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.
December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.